UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2026
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
EXHIBIT INDEX
|
Exhibit
Number
|
Description
|
|
99.1
|
11
August 2026 - “Cash tender offer
- outstanding 2027 3.375% Notes”
|
99.1
Haleon plc: Cash tender offer for outstanding 2027 3.375% Fixed
Rate Notes
Note: This announcement is being released in accordance with DTR
6.3.10 R. In the United Kingdom, the Tender Offer is only available
to relevant persons, as described under "Non-U.S. Distribution
Restrictions - United Kingdom" in the full announcement linked
below.
11 August 2026: Haleon
plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today
announces
that its wholly owned subsidiary, Haleon US Capital LLC (the
"Offeror") is offering to buy back any and all of its
outstanding $1,999,350,000 3.375% Fixed Rate Senior Notes due March
2027. Bondholders will receive a price equal to the Total
Consideration based on the Reference Yield and the Fixed Spread
plus Accrued Interest (each as defined in the full announcement)
(the "Tender Offer").
This Tender Offer is in line with Haleon's previously stated
capital allocation priorities. Together, with the planned issue of
new bonds, it is expected to help the Company to proactively manage
and optimise its debt portfolio. The full announcement is available
at
http://www.rns-pdf.londonstockexchange.com/rns/2411Q_1-2026-8-11.pdf.
The full announcement will also be available on the Haleon
website www.haleon.com/investors,
and has been submitted in full unedited text to the Financial
Conduct Authority's National Storage Mechanism and will shortly be
available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Enquiries
|
Investors
|
Media
|
|
Jo
Russell
|
+44
7787 392441
|
Zoë Bird
|
+44
7736 746167
|
|
Rakesh
Patel
|
+44
7552 484646
|
Gemma
Thomas
|
+44 7985 175048
|
|
Email: investor-relations@haleon.com
|
Email: corporate.media@haleon.com
|
|
|
|
|
Treasury
|
|
|
Mike
Rowe
|
+44
7775 012365
|
|
|
Ben
Checkland
|
+44
7823 370368
|
|
|
Email: cf-treasury@haleon.com
|
|
About Haleon
Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused
on better everyday health. Our people, our brands, our research,
our investment and our innovation are aimed at improving the
everyday health of consumers. Our product portfolio spans six major
categories - Oral Health, Vitamins, Minerals and Supplements (VMS),
Pain Relief, Respiratory Health, Digestive Health and Therapeutic
Skin Health and Other. Our superior brands - such
as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are trusted by more than one billion
consumers and are recommended by health professionals around the
world.
For more information, please visit www.haleon.com.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
Date:
August 11, 2026
|
By:
|
/s/
Amanda Mellor
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|
